JNCCN 360 - Immunotherapy

Advertisement

Advertisement

Heinz-Josef Lenz, MD, on Reducing Ipilimumab Dose: What Are the Ramifications?

Mansoor Raza Mirza, MD, on the Potential Role of PARP Inhibition Plus Immunotherapy in Ovarian Cancer

Paul G. Richardson, MD, on Multiple Myeloma: Results From the OPTIMISMM Trial

Recent

DREAMM-4 Trial Update of Belantamab Mafodotin in Myeloma

KEYNOTE-629: Pembrolizumab in Metastatic Cutaneous Squamous Cell Carcinoma

Novel First-in-Class Agent Shows Activity in High-Grade Serous Ovarian Cancer

Front-Line Immunotherapy for Locally Advanced Basal Cell Carcinoma: Case Studies

Published

Medical Literature

Phase III Trial of Triplet Regimen for HER2-Positive Metastatic Breast Cancer

First-line Osimertinib and Bevacizumab Treatment in Metastatic EGFR-Mutant Lung Cancer

Combination Therapy of Vaccine and Durvalumab in Advanced Ovarian Cancer

First-in-Human Phase I Trial of Novel Vaccine in Metastatic Prostate Cancer

Ongoing

Modest Responses With Immunotherapy Combo for Advanced Ovarian Cancer

Emerging Considerations in Triple-Negative Breast Cancer: Focus on Immunotherapy

BCOP Test-Advances in Targeted Therapy and Immunotherapy For The Treatment of Kidney Cancer

NCCN Pharmacy Updates: Advances in Targeted Therapy and Immunotherapy for the Treatment of Kidney Cancer

Available

Clinical Trials

Center for Immunotherapy Clinical Research Trials

Cancer Research Institute Immunotherapy Clinical Trials

ClinicalTrials.gov Immunotherapy

Immunotherapy Clinical Trials at Fred Hutch Cancer Research Center

NCCN Resources

Copyright © 2020 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.